DECIBEL THERAPEUTICS, INC. MILWAUKEE, Aug. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Decibel (NASDAQ: DBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron.
Click here to learn how to join the action https://www.ademilaw.com/case/decibel-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Decibel stockholders are expected to receive only $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel's lead investigational candidate, DB-OTO, within specified time periods. The transaction agreement unreasonably limits competing transactions for Decibel by imposing a significant penalty if Decibel accepts a competing bid. Decibel insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Decibel's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Decibel common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/decibel-therapeutics-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-decibel-therapeutics-inc-has-obtained-a-fair-price-in-its-transaction-with-regeneron-301896885.html
SOURCE Ademi LLP
